nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—ABL1—liver cancer	0.266	0.838	CbGaD
Imatinib—HIPK4—Sorafenib—liver cancer	0.0844	0.183	CbGbCtD
Imatinib—PDGFRA—Sorafenib—liver cancer	0.0758	0.165	CbGbCtD
Imatinib—CSF1R—Sorafenib—liver cancer	0.0758	0.165	CbGbCtD
Imatinib—KIT—Sorafenib—liver cancer	0.0758	0.165	CbGbCtD
Imatinib—PDGFRB—Sorafenib—liver cancer	0.069	0.15	CbGbCtD
Imatinib—ALB—liver cancer	0.0515	0.162	CbGaD
Imatinib—ABCG2—Sorafenib—liver cancer	0.0125	0.0272	CbGbCtD
Imatinib—CYP3A7—Sorafenib—liver cancer	0.00925	0.0201	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Sorafenib—liver cancer	0.00925	0.0201	CbGbCtD
Imatinib—ABCG2—Doxorubicin—liver cancer	0.0076	0.0165	CbGbCtD
Imatinib—CYP3A5—Sorafenib—liver cancer	0.00694	0.0151	CbGbCtD
Imatinib—CYP2C19—Sorafenib—liver cancer	0.00559	0.0122	CbGbCtD
Imatinib—CYP1A2—Sorafenib—liver cancer	0.00516	0.0112	CbGbCtD
Imatinib—CYP2C9—Sorafenib—liver cancer	0.00465	0.0101	CbGbCtD
Imatinib—ABCB1—Sorafenib—liver cancer	0.00451	0.00981	CbGbCtD
Imatinib—CYP2D6—Sorafenib—liver cancer	0.00425	0.00924	CbGbCtD
Imatinib—ORM1—bile—liver cancer	0.00306	0.145	CbGeAlD
Imatinib—ABCB1—Doxorubicin—liver cancer	0.00274	0.00595	CbGbCtD
Imatinib—CYP3A4—Sorafenib—liver cancer	0.0027	0.00588	CbGbCtD
Imatinib—CYP2D6—Doxorubicin—liver cancer	0.00258	0.00561	CbGbCtD
Imatinib—CYP3A4—Doxorubicin—liver cancer	0.00164	0.00357	CbGbCtD
Imatinib—CA9—gall bladder—liver cancer	0.00145	0.0687	CbGeAlD
Imatinib—PDGFRA—gall bladder—liver cancer	0.00116	0.0551	CbGeAlD
Imatinib—Nilotinib—MAPK8—liver cancer	0.00105	0.235	CrCbGaD
Imatinib—Nilotinib—MAPK14—liver cancer	0.00101	0.227	CrCbGaD
Imatinib—KIT—gall bladder—liver cancer	0.000927	0.044	CbGeAlD
Imatinib—PDGFRB—gall bladder—liver cancer	0.000905	0.043	CbGeAlD
Imatinib—ORM1—gall bladder—liver cancer	0.000849	0.0403	CbGeAlD
Imatinib—DDR1—liver—liver cancer	0.000751	0.0357	CbGeAlD
Imatinib—ALB—gall bladder—liver cancer	0.000744	0.0354	CbGeAlD
Imatinib—PDGFRA—embryo—liver cancer	0.000735	0.0349	CbGeAlD
Imatinib—Ponatinib—ABL1—liver cancer	0.000721	0.162	CrCbGaD
Imatinib—CSF1R—embryo—liver cancer	0.000647	0.0307	CbGeAlD
Imatinib—Ponatinib—KDR—liver cancer	0.000613	0.137	CrCbGaD
Imatinib—KIT—embryo—liver cancer	0.000587	0.0279	CbGeAlD
Imatinib—PDGFRB—embryo—liver cancer	0.000574	0.0273	CbGeAlD
Imatinib—CA2—gall bladder—liver cancer	0.000549	0.0261	CbGeAlD
Imatinib—Nilotinib—ABL1—liver cancer	0.000532	0.119	CrCbGaD
Imatinib—Nilotinib—BRAF—liver cancer	0.000532	0.119	CrCbGaD
Imatinib—ABL1—embryo—liver cancer	0.000511	0.0243	CbGeAlD
Imatinib—ABL2—liver—liver cancer	0.00049	0.0233	CbGeAlD
Imatinib—PIP4K2C—liver—liver cancer	0.000464	0.022	CbGeAlD
Imatinib—CA3—liver—liver cancer	0.000443	0.0211	CbGeAlD
Imatinib—LCK—liver—liver cancer	0.000412	0.0196	CbGeAlD
Imatinib—CA14—liver—liver cancer	0.000402	0.0191	CbGeAlD
Imatinib—CYP3A7—liver—liver cancer	0.000393	0.0187	CbGeAlD
Imatinib—ABL1—Doxorubicin—Epirubicin—liver cancer	0.000381	0.173	CbGdCrCtD
Imatinib—ABL1—Idarubicin—Epirubicin—liver cancer	0.000381	0.173	CbGdCrCtD
Imatinib—ABL1—Daunorubicin—Epirubicin—liver cancer	0.000381	0.173	CbGdCrCtD
Imatinib—ABL1—Idarubicin—Doxorubicin—liver cancer	0.000353	0.16	CbGdCrCtD
Imatinib—ABL1—Epirubicin—Doxorubicin—liver cancer	0.000353	0.16	CbGdCrCtD
Imatinib—ABL1—Daunorubicin—Doxorubicin—liver cancer	0.000353	0.16	CbGdCrCtD
Imatinib—CA2—embryo—liver cancer	0.000348	0.0165	CbGeAlD
Imatinib—NQO2—liver—liver cancer	0.000341	0.0162	CbGeAlD
Imatinib—PDGFRA—liver—liver cancer	0.00034	0.0162	CbGeAlD
Imatinib—CYP3A7-CYP3A51P—liver—liver cancer	0.000334	0.0159	CbGeAlD
Imatinib—CSF1R—liver—liver cancer	0.000299	0.0142	CbGeAlD
Imatinib—SLC47A1—liver—liver cancer	0.000273	0.013	CbGeAlD
Imatinib—KIT—liver—liver cancer	0.000272	0.0129	CbGeAlD
Imatinib—PDGFRB—liver—liver cancer	0.000265	0.0126	CbGeAlD
Imatinib—ORM1—liver—liver cancer	0.000249	0.0118	CbGeAlD
Imatinib—CA1—liver—liver cancer	0.000248	0.0118	CbGeAlD
Imatinib—ABL1—liver—liver cancer	0.000236	0.0112	CbGeAlD
Imatinib—SLC22A1—liver—liver cancer	0.000228	0.0108	CbGeAlD
Imatinib—ALB—liver—liver cancer	0.000218	0.0104	CbGeAlD
Imatinib—CYP2C19—liver—liver cancer	0.000176	0.00835	CbGeAlD
Imatinib—CA2—liver—liver cancer	0.000161	0.00765	CbGeAlD
Imatinib—ABCB1—embryo—liver cancer	0.000159	0.00756	CbGeAlD
Imatinib—ABCG2—liver—liver cancer	0.000149	0.00709	CbGeAlD
Imatinib—CYP1A2—liver—liver cancer	0.000144	0.00682	CbGeAlD
Imatinib—CYP3A5—liver—liver cancer	0.000138	0.00658	CbGeAlD
Imatinib—CYP2C9—liver—liver cancer	0.000136	0.00648	CbGeAlD
Imatinib—CYP3A4—liver—liver cancer	0.000104	0.00494	CbGeAlD
Imatinib—CYP2D6—liver—liver cancer	0.000102	0.00486	CbGeAlD
Imatinib—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000101	0.00101	CcSEcCtD
Imatinib—Cardiac arrest—Doxorubicin—liver cancer	0.000101	0.00101	CcSEcCtD
Imatinib—Dizziness—Sorafenib—liver cancer	0.000101	0.001	CcSEcCtD
Imatinib—Abdominal distension—Epirubicin—liver cancer	9.95e-05	0.000994	CcSEcCtD
Imatinib—Blood creatinine increased—Doxorubicin—liver cancer	9.91e-05	0.00099	CcSEcCtD
Imatinib—Influenza—Epirubicin—liver cancer	9.88e-05	0.000987	CcSEcCtD
Imatinib—Dysphagia—Epirubicin—liver cancer	9.88e-05	0.000987	CcSEcCtD
Imatinib—Dehydration—Doxorubicin—liver cancer	9.84e-05	0.000983	CcSEcCtD
Imatinib—Eosinophilia—Epirubicin—liver cancer	9.79e-05	0.000978	CcSEcCtD
Imatinib—Dry skin—Doxorubicin—liver cancer	9.7e-05	0.000969	CcSEcCtD
Imatinib—Pancreatitis—Epirubicin—liver cancer	9.69e-05	0.000968	CcSEcCtD
Imatinib—Vomiting—Sorafenib—liver cancer	9.67e-05	0.000966	CcSEcCtD
Imatinib—Abdominal pain upper—Doxorubicin—liver cancer	9.67e-05	0.000965	CcSEcCtD
Imatinib—Hypokalaemia—Doxorubicin—liver cancer	9.63e-05	0.000962	CcSEcCtD
Imatinib—Angina pectoris—Epirubicin—liver cancer	9.63e-05	0.000962	CcSEcCtD
Imatinib—Rash—Sorafenib—liver cancer	9.59e-05	0.000958	CcSEcCtD
Imatinib—Dermatitis—Sorafenib—liver cancer	9.58e-05	0.000957	CcSEcCtD
Imatinib—Breast disorder—Doxorubicin—liver cancer	9.56e-05	0.000955	CcSEcCtD
Imatinib—Toxic epidermal necrolysis—Doxorubicin—liver cancer	9.53e-05	0.000952	CcSEcCtD
Imatinib—Aspartate aminotransferase increased—Doxorubicin—liver cancer	9.53e-05	0.000952	CcSEcCtD
Imatinib—Headache—Sorafenib—liver cancer	9.53e-05	0.000952	CcSEcCtD
Imatinib—Nasopharyngitis—Doxorubicin—liver cancer	9.46e-05	0.000945	CcSEcCtD
Imatinib—Pancytopenia—Epirubicin—liver cancer	9.39e-05	0.000938	CcSEcCtD
Imatinib—Gastritis—Doxorubicin—liver cancer	9.37e-05	0.000935	CcSEcCtD
Imatinib—Muscular weakness—Doxorubicin—liver cancer	9.33e-05	0.000932	CcSEcCtD
Imatinib—Alanine aminotransferase increased—Doxorubicin—liver cancer	9.33e-05	0.000932	CcSEcCtD
Imatinib—Neutropenia—Epirubicin—liver cancer	9.24e-05	0.000923	CcSEcCtD
Imatinib—Abdominal distension—Doxorubicin—liver cancer	9.21e-05	0.00092	CcSEcCtD
Imatinib—Upper respiratory tract infection—Epirubicin—liver cancer	9.19e-05	0.000918	CcSEcCtD
Imatinib—Influenza—Doxorubicin—liver cancer	9.15e-05	0.000914	CcSEcCtD
Imatinib—Dysphagia—Doxorubicin—liver cancer	9.15e-05	0.000914	CcSEcCtD
Imatinib—Pollakiuria—Epirubicin—liver cancer	9.13e-05	0.000912	CcSEcCtD
Imatinib—Eosinophilia—Doxorubicin—liver cancer	9.06e-05	0.000905	CcSEcCtD
Imatinib—Nausea—Sorafenib—liver cancer	9.03e-05	0.000902	CcSEcCtD
Imatinib—Photosensitivity reaction—Epirubicin—liver cancer	9.02e-05	0.000901	CcSEcCtD
Imatinib—Weight increased—Epirubicin—liver cancer	9e-05	0.000899	CcSEcCtD
Imatinib—Pancreatitis—Doxorubicin—liver cancer	8.97e-05	0.000896	CcSEcCtD
Imatinib—Weight decreased—Epirubicin—liver cancer	8.94e-05	0.000893	CcSEcCtD
Imatinib—Hyperglycaemia—Epirubicin—liver cancer	8.92e-05	0.000891	CcSEcCtD
Imatinib—Angina pectoris—Doxorubicin—liver cancer	8.91e-05	0.00089	CcSEcCtD
Imatinib—Pneumonia—Epirubicin—liver cancer	8.86e-05	0.000885	CcSEcCtD
Imatinib—Infestation NOS—Epirubicin—liver cancer	8.81e-05	0.00088	CcSEcCtD
Imatinib—Infestation—Epirubicin—liver cancer	8.81e-05	0.00088	CcSEcCtD
Imatinib—Stevens-Johnson syndrome—Epirubicin—liver cancer	8.74e-05	0.000873	CcSEcCtD
Imatinib—Pancytopenia—Doxorubicin—liver cancer	8.69e-05	0.000868	CcSEcCtD
Imatinib—Renal failure—Epirubicin—liver cancer	8.66e-05	0.000865	CcSEcCtD
Imatinib—Neuropathy peripheral—Epirubicin—liver cancer	8.64e-05	0.000863	CcSEcCtD
Imatinib—Jaundice—Epirubicin—liver cancer	8.59e-05	0.000858	CcSEcCtD
Imatinib—Stomatitis—Epirubicin—liver cancer	8.59e-05	0.000858	CcSEcCtD
Imatinib—Urinary tract infection—Epirubicin—liver cancer	8.57e-05	0.000856	CcSEcCtD
Imatinib—Conjunctivitis—Epirubicin—liver cancer	8.57e-05	0.000856	CcSEcCtD
Imatinib—Neutropenia—Doxorubicin—liver cancer	8.55e-05	0.000854	CcSEcCtD
Imatinib—Upper respiratory tract infection—Doxorubicin—liver cancer	8.5e-05	0.000849	CcSEcCtD
Imatinib—Sweating—Epirubicin—liver cancer	8.45e-05	0.000844	CcSEcCtD
Imatinib—Pollakiuria—Doxorubicin—liver cancer	8.45e-05	0.000844	CcSEcCtD
Imatinib—Haematuria—Epirubicin—liver cancer	8.4e-05	0.000839	CcSEcCtD
Imatinib—Photosensitivity reaction—Doxorubicin—liver cancer	8.35e-05	0.000834	CcSEcCtD
Imatinib—Hepatobiliary disease—Epirubicin—liver cancer	8.34e-05	0.000833	CcSEcCtD
Imatinib—Weight increased—Doxorubicin—liver cancer	8.32e-05	0.000831	CcSEcCtD
Imatinib—Epistaxis—Epirubicin—liver cancer	8.31e-05	0.00083	CcSEcCtD
Imatinib—Weight decreased—Doxorubicin—liver cancer	8.27e-05	0.000827	CcSEcCtD
Imatinib—Sinusitis—Epirubicin—liver cancer	8.27e-05	0.000826	CcSEcCtD
Imatinib—Hyperglycaemia—Doxorubicin—liver cancer	8.25e-05	0.000824	CcSEcCtD
Imatinib—Agranulocytosis—Epirubicin—liver cancer	8.22e-05	0.000822	CcSEcCtD
Imatinib—Pneumonia—Doxorubicin—liver cancer	8.2e-05	0.000819	CcSEcCtD
Imatinib—Infestation NOS—Doxorubicin—liver cancer	8.15e-05	0.000815	CcSEcCtD
Imatinib—Infestation—Doxorubicin—liver cancer	8.15e-05	0.000815	CcSEcCtD
Imatinib—Stevens-Johnson syndrome—Doxorubicin—liver cancer	8.08e-05	0.000808	CcSEcCtD
Imatinib—Renal failure—Doxorubicin—liver cancer	8.02e-05	0.000801	CcSEcCtD
Imatinib—Neuropathy peripheral—Doxorubicin—liver cancer	7.99e-05	0.000798	CcSEcCtD
Imatinib—Haemoglobin—Epirubicin—liver cancer	7.95e-05	0.000794	CcSEcCtD
Imatinib—Jaundice—Doxorubicin—liver cancer	7.95e-05	0.000794	CcSEcCtD
Imatinib—Stomatitis—Doxorubicin—liver cancer	7.95e-05	0.000794	CcSEcCtD
Imatinib—Rhinitis—Epirubicin—liver cancer	7.93e-05	0.000792	CcSEcCtD
Imatinib—Urinary tract infection—Doxorubicin—liver cancer	7.93e-05	0.000792	CcSEcCtD
Imatinib—Conjunctivitis—Doxorubicin—liver cancer	7.93e-05	0.000792	CcSEcCtD
Imatinib—Hepatitis—Epirubicin—liver cancer	7.91e-05	0.00079	CcSEcCtD
Imatinib—Haemorrhage—Epirubicin—liver cancer	7.91e-05	0.00079	CcSEcCtD
Imatinib—Hypoaesthesia—Epirubicin—liver cancer	7.87e-05	0.000786	CcSEcCtD
Imatinib—Pharyngitis—Epirubicin—liver cancer	7.85e-05	0.000784	CcSEcCtD
Imatinib—Sweating—Doxorubicin—liver cancer	7.82e-05	0.000781	CcSEcCtD
Imatinib—Urinary tract disorder—Epirubicin—liver cancer	7.81e-05	0.00078	CcSEcCtD
Imatinib—Oedema peripheral—Epirubicin—liver cancer	7.79e-05	0.000779	CcSEcCtD
Imatinib—Haematuria—Doxorubicin—liver cancer	7.78e-05	0.000777	CcSEcCtD
Imatinib—Connective tissue disorder—Epirubicin—liver cancer	7.77e-05	0.000777	CcSEcCtD
Imatinib—Urethral disorder—Epirubicin—liver cancer	7.76e-05	0.000775	CcSEcCtD
Imatinib—Hepatobiliary disease—Doxorubicin—liver cancer	7.71e-05	0.00077	CcSEcCtD
Imatinib—Epistaxis—Doxorubicin—liver cancer	7.69e-05	0.000768	CcSEcCtD
Imatinib—Sinusitis—Doxorubicin—liver cancer	7.65e-05	0.000764	CcSEcCtD
Imatinib—Agranulocytosis—Doxorubicin—liver cancer	7.61e-05	0.00076	CcSEcCtD
Imatinib—Erythema multiforme—Epirubicin—liver cancer	7.48e-05	0.000747	CcSEcCtD
Imatinib—Eye disorder—Epirubicin—liver cancer	7.39e-05	0.000739	CcSEcCtD
Imatinib—Tinnitus—Epirubicin—liver cancer	7.38e-05	0.000737	CcSEcCtD
Imatinib—Haemoglobin—Doxorubicin—liver cancer	7.36e-05	0.000735	CcSEcCtD
Imatinib—ABCB1—liver—liver cancer	7.35e-05	0.0035	CbGeAlD
Imatinib—Flushing—Epirubicin—liver cancer	7.34e-05	0.000733	CcSEcCtD
Imatinib—Cardiac disorder—Epirubicin—liver cancer	7.34e-05	0.000733	CcSEcCtD
Imatinib—Rhinitis—Doxorubicin—liver cancer	7.34e-05	0.000733	CcSEcCtD
Imatinib—Haemorrhage—Doxorubicin—liver cancer	7.32e-05	0.000731	CcSEcCtD
Imatinib—Hepatitis—Doxorubicin—liver cancer	7.32e-05	0.000731	CcSEcCtD
Imatinib—Hypoaesthesia—Doxorubicin—liver cancer	7.28e-05	0.000728	CcSEcCtD
Imatinib—Pharyngitis—Doxorubicin—liver cancer	7.27e-05	0.000726	CcSEcCtD
Imatinib—Urinary tract disorder—Doxorubicin—liver cancer	7.23e-05	0.000722	CcSEcCtD
Imatinib—Oedema peripheral—Doxorubicin—liver cancer	7.21e-05	0.00072	CcSEcCtD
Imatinib—Connective tissue disorder—Doxorubicin—liver cancer	7.19e-05	0.000719	CcSEcCtD
Imatinib—Angiopathy—Epirubicin—liver cancer	7.18e-05	0.000717	CcSEcCtD
Imatinib—Urethral disorder—Doxorubicin—liver cancer	7.18e-05	0.000717	CcSEcCtD
Imatinib—Immune system disorder—Epirubicin—liver cancer	7.15e-05	0.000714	CcSEcCtD
Imatinib—Mediastinal disorder—Epirubicin—liver cancer	7.13e-05	0.000712	CcSEcCtD
Imatinib—Chills—Epirubicin—liver cancer	7.1e-05	0.000709	CcSEcCtD
Imatinib—Arrhythmia—Epirubicin—liver cancer	7.07e-05	0.000706	CcSEcCtD
Imatinib—Alopecia—Epirubicin—liver cancer	6.99e-05	0.000698	CcSEcCtD
Imatinib—Mental disorder—Epirubicin—liver cancer	6.93e-05	0.000692	CcSEcCtD
Imatinib—Erythema multiforme—Doxorubicin—liver cancer	6.92e-05	0.000691	CcSEcCtD
Imatinib—Erythema—Epirubicin—liver cancer	6.89e-05	0.000688	CcSEcCtD
Imatinib—Malnutrition—Epirubicin—liver cancer	6.89e-05	0.000688	CcSEcCtD
Imatinib—Eye disorder—Doxorubicin—liver cancer	6.84e-05	0.000683	CcSEcCtD
Imatinib—Tinnitus—Doxorubicin—liver cancer	6.83e-05	0.000682	CcSEcCtD
Imatinib—Flushing—Doxorubicin—liver cancer	6.79e-05	0.000679	CcSEcCtD
Imatinib—Cardiac disorder—Doxorubicin—liver cancer	6.79e-05	0.000679	CcSEcCtD
Imatinib—Flatulence—Epirubicin—liver cancer	6.79e-05	0.000678	CcSEcCtD
Imatinib—Dysgeusia—Epirubicin—liver cancer	6.74e-05	0.000674	CcSEcCtD
Imatinib—Back pain—Epirubicin—liver cancer	6.66e-05	0.000665	CcSEcCtD
Imatinib—Angiopathy—Doxorubicin—liver cancer	6.64e-05	0.000663	CcSEcCtD
Imatinib—Muscle spasms—Epirubicin—liver cancer	6.62e-05	0.000661	CcSEcCtD
Imatinib—Immune system disorder—Doxorubicin—liver cancer	6.61e-05	0.00066	CcSEcCtD
Imatinib—Mediastinal disorder—Doxorubicin—liver cancer	6.6e-05	0.000659	CcSEcCtD
Imatinib—Chills—Doxorubicin—liver cancer	6.57e-05	0.000656	CcSEcCtD
Imatinib—Arrhythmia—Doxorubicin—liver cancer	6.54e-05	0.000653	CcSEcCtD
Imatinib—Vision blurred—Epirubicin—liver cancer	6.49e-05	0.000648	CcSEcCtD
Imatinib—Alopecia—Doxorubicin—liver cancer	6.47e-05	0.000646	CcSEcCtD
Imatinib—Mental disorder—Doxorubicin—liver cancer	6.41e-05	0.000641	CcSEcCtD
Imatinib—Ill-defined disorder—Epirubicin—liver cancer	6.39e-05	0.000638	CcSEcCtD
Imatinib—Erythema—Doxorubicin—liver cancer	6.37e-05	0.000637	CcSEcCtD
Imatinib—Malnutrition—Doxorubicin—liver cancer	6.37e-05	0.000637	CcSEcCtD
Imatinib—Anaemia—Epirubicin—liver cancer	6.37e-05	0.000636	CcSEcCtD
Imatinib—Flatulence—Doxorubicin—liver cancer	6.28e-05	0.000627	CcSEcCtD
Imatinib—Dysgeusia—Doxorubicin—liver cancer	6.24e-05	0.000623	CcSEcCtD
Imatinib—Malaise—Epirubicin—liver cancer	6.21e-05	0.00062	CcSEcCtD
Imatinib—Vertigo—Epirubicin—liver cancer	6.19e-05	0.000618	CcSEcCtD
Imatinib—Syncope—Epirubicin—liver cancer	6.18e-05	0.000617	CcSEcCtD
Imatinib—Leukopenia—Epirubicin—liver cancer	6.17e-05	0.000616	CcSEcCtD
Imatinib—Back pain—Doxorubicin—liver cancer	6.16e-05	0.000616	CcSEcCtD
Imatinib—Muscle spasms—Doxorubicin—liver cancer	6.13e-05	0.000612	CcSEcCtD
Imatinib—Palpitations—Epirubicin—liver cancer	6.09e-05	0.000608	CcSEcCtD
Imatinib—Loss of consciousness—Epirubicin—liver cancer	6.05e-05	0.000605	CcSEcCtD
Imatinib—Cough—Epirubicin—liver cancer	6.01e-05	0.0006	CcSEcCtD
Imatinib—Vision blurred—Doxorubicin—liver cancer	6.01e-05	0.0006	CcSEcCtD
Imatinib—Convulsion—Epirubicin—liver cancer	5.97e-05	0.000596	CcSEcCtD
Imatinib—Hypertension—Epirubicin—liver cancer	5.95e-05	0.000594	CcSEcCtD
Imatinib—Ill-defined disorder—Doxorubicin—liver cancer	5.91e-05	0.000591	CcSEcCtD
Imatinib—Anaemia—Doxorubicin—liver cancer	5.89e-05	0.000588	CcSEcCtD
Imatinib—Arthralgia—Epirubicin—liver cancer	5.86e-05	0.000586	CcSEcCtD
Imatinib—Chest pain—Epirubicin—liver cancer	5.86e-05	0.000586	CcSEcCtD
Imatinib—Myalgia—Epirubicin—liver cancer	5.86e-05	0.000586	CcSEcCtD
Imatinib—Anxiety—Epirubicin—liver cancer	5.84e-05	0.000584	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	5.82e-05	0.000582	CcSEcCtD
Imatinib—Discomfort—Epirubicin—liver cancer	5.79e-05	0.000579	CcSEcCtD
Imatinib—Malaise—Doxorubicin—liver cancer	5.75e-05	0.000574	CcSEcCtD
Imatinib—Dry mouth—Epirubicin—liver cancer	5.73e-05	0.000573	CcSEcCtD
Imatinib—Vertigo—Doxorubicin—liver cancer	5.73e-05	0.000572	CcSEcCtD
Imatinib—Syncope—Doxorubicin—liver cancer	5.71e-05	0.000571	CcSEcCtD
Imatinib—Leukopenia—Doxorubicin—liver cancer	5.7e-05	0.00057	CcSEcCtD
Imatinib—Confusional state—Epirubicin—liver cancer	5.67e-05	0.000566	CcSEcCtD
Imatinib—Palpitations—Doxorubicin—liver cancer	5.63e-05	0.000563	CcSEcCtD
Imatinib—Anaphylactic shock—Epirubicin—liver cancer	5.62e-05	0.000561	CcSEcCtD
Imatinib—Oedema—Epirubicin—liver cancer	5.62e-05	0.000561	CcSEcCtD
Imatinib—Loss of consciousness—Doxorubicin—liver cancer	5.6e-05	0.000559	CcSEcCtD
Imatinib—Infection—Epirubicin—liver cancer	5.58e-05	0.000558	CcSEcCtD
Imatinib—Cough—Doxorubicin—liver cancer	5.56e-05	0.000555	CcSEcCtD
Imatinib—Shock—Epirubicin—liver cancer	5.53e-05	0.000552	CcSEcCtD
Imatinib—Convulsion—Doxorubicin—liver cancer	5.52e-05	0.000552	CcSEcCtD
Imatinib—Nervous system disorder—Epirubicin—liver cancer	5.51e-05	0.000551	CcSEcCtD
Imatinib—Thrombocytopenia—Epirubicin—liver cancer	5.5e-05	0.00055	CcSEcCtD
Imatinib—Hypertension—Doxorubicin—liver cancer	5.5e-05	0.00055	CcSEcCtD
Imatinib—Tachycardia—Epirubicin—liver cancer	5.49e-05	0.000548	CcSEcCtD
Imatinib—Skin disorder—Epirubicin—liver cancer	5.46e-05	0.000545	CcSEcCtD
Imatinib—Hyperhidrosis—Epirubicin—liver cancer	5.43e-05	0.000543	CcSEcCtD
Imatinib—Chest pain—Doxorubicin—liver cancer	5.43e-05	0.000542	CcSEcCtD
Imatinib—Arthralgia—Doxorubicin—liver cancer	5.43e-05	0.000542	CcSEcCtD
Imatinib—Myalgia—Doxorubicin—liver cancer	5.43e-05	0.000542	CcSEcCtD
Imatinib—Anxiety—Doxorubicin—liver cancer	5.41e-05	0.00054	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	5.39e-05	0.000538	CcSEcCtD
Imatinib—Discomfort—Doxorubicin—liver cancer	5.36e-05	0.000535	CcSEcCtD
Imatinib—Anorexia—Epirubicin—liver cancer	5.36e-05	0.000535	CcSEcCtD
Imatinib—Dry mouth—Doxorubicin—liver cancer	5.31e-05	0.00053	CcSEcCtD
Imatinib—Hypotension—Epirubicin—liver cancer	5.25e-05	0.000525	CcSEcCtD
Imatinib—Confusional state—Doxorubicin—liver cancer	5.24e-05	0.000524	CcSEcCtD
Imatinib—Anaphylactic shock—Doxorubicin—liver cancer	5.2e-05	0.00052	CcSEcCtD
Imatinib—Oedema—Doxorubicin—liver cancer	5.2e-05	0.00052	CcSEcCtD
Imatinib—Infection—Doxorubicin—liver cancer	5.17e-05	0.000516	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Epirubicin—liver cancer	5.12e-05	0.000512	CcSEcCtD
Imatinib—Shock—Doxorubicin—liver cancer	5.12e-05	0.000511	CcSEcCtD
Imatinib—Nervous system disorder—Doxorubicin—liver cancer	5.1e-05	0.000509	CcSEcCtD
Imatinib—Thrombocytopenia—Doxorubicin—liver cancer	5.09e-05	0.000509	CcSEcCtD
Imatinib—Insomnia—Epirubicin—liver cancer	5.08e-05	0.000508	CcSEcCtD
Imatinib—Tachycardia—Doxorubicin—liver cancer	5.08e-05	0.000507	CcSEcCtD
Imatinib—Skin disorder—Doxorubicin—liver cancer	5.05e-05	0.000505	CcSEcCtD
Imatinib—Paraesthesia—Epirubicin—liver cancer	5.05e-05	0.000504	CcSEcCtD
Imatinib—Hyperhidrosis—Doxorubicin—liver cancer	5.03e-05	0.000502	CcSEcCtD
Imatinib—Dyspnoea—Epirubicin—liver cancer	5.01e-05	0.000501	CcSEcCtD
Imatinib—Somnolence—Epirubicin—liver cancer	5e-05	0.000499	CcSEcCtD
Imatinib—Anorexia—Doxorubicin—liver cancer	4.96e-05	0.000495	CcSEcCtD
Imatinib—Dyspepsia—Epirubicin—liver cancer	4.95e-05	0.000494	CcSEcCtD
Imatinib—Decreased appetite—Epirubicin—liver cancer	4.89e-05	0.000488	CcSEcCtD
Imatinib—Hypotension—Doxorubicin—liver cancer	4.86e-05	0.000485	CcSEcCtD
Imatinib—Gastrointestinal disorder—Epirubicin—liver cancer	4.85e-05	0.000485	CcSEcCtD
Imatinib—Fatigue—Epirubicin—liver cancer	4.85e-05	0.000484	CcSEcCtD
Imatinib—Pain—Epirubicin—liver cancer	4.81e-05	0.00048	CcSEcCtD
Imatinib—Constipation—Epirubicin—liver cancer	4.81e-05	0.00048	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Doxorubicin—liver cancer	4.74e-05	0.000473	CcSEcCtD
Imatinib—Insomnia—Doxorubicin—liver cancer	4.7e-05	0.00047	CcSEcCtD
Imatinib—Paraesthesia—Doxorubicin—liver cancer	4.67e-05	0.000467	CcSEcCtD
Imatinib—Dyspnoea—Doxorubicin—liver cancer	4.64e-05	0.000463	CcSEcCtD
Imatinib—Feeling abnormal—Epirubicin—liver cancer	4.63e-05	0.000463	CcSEcCtD
Imatinib—Somnolence—Doxorubicin—liver cancer	4.62e-05	0.000462	CcSEcCtD
Imatinib—Gastrointestinal pain—Epirubicin—liver cancer	4.6e-05	0.000459	CcSEcCtD
Imatinib—Dyspepsia—Doxorubicin—liver cancer	4.58e-05	0.000457	CcSEcCtD
Imatinib—Decreased appetite—Doxorubicin—liver cancer	4.52e-05	0.000452	CcSEcCtD
Imatinib—Gastrointestinal disorder—Doxorubicin—liver cancer	4.49e-05	0.000449	CcSEcCtD
Imatinib—Fatigue—Doxorubicin—liver cancer	4.48e-05	0.000448	CcSEcCtD
Imatinib—Urticaria—Epirubicin—liver cancer	4.47e-05	0.000446	CcSEcCtD
Imatinib—Pain—Doxorubicin—liver cancer	4.45e-05	0.000444	CcSEcCtD
Imatinib—Constipation—Doxorubicin—liver cancer	4.45e-05	0.000444	CcSEcCtD
Imatinib—Body temperature increased—Epirubicin—liver cancer	4.44e-05	0.000444	CcSEcCtD
Imatinib—Abdominal pain—Epirubicin—liver cancer	4.44e-05	0.000444	CcSEcCtD
Imatinib—Feeling abnormal—Doxorubicin—liver cancer	4.29e-05	0.000428	CcSEcCtD
Imatinib—Gastrointestinal pain—Doxorubicin—liver cancer	4.25e-05	0.000425	CcSEcCtD
Imatinib—Hypersensitivity—Epirubicin—liver cancer	4.14e-05	0.000414	CcSEcCtD
Imatinib—Urticaria—Doxorubicin—liver cancer	4.13e-05	0.000413	CcSEcCtD
Imatinib—Abdominal pain—Doxorubicin—liver cancer	4.11e-05	0.000411	CcSEcCtD
Imatinib—Body temperature increased—Doxorubicin—liver cancer	4.11e-05	0.000411	CcSEcCtD
Imatinib—Asthenia—Epirubicin—liver cancer	4.03e-05	0.000403	CcSEcCtD
Imatinib—Pruritus—Epirubicin—liver cancer	3.98e-05	0.000397	CcSEcCtD
Imatinib—Diarrhoea—Epirubicin—liver cancer	3.85e-05	0.000384	CcSEcCtD
Imatinib—Hypersensitivity—Doxorubicin—liver cancer	3.83e-05	0.000383	CcSEcCtD
Imatinib—Asthenia—Doxorubicin—liver cancer	3.73e-05	0.000373	CcSEcCtD
Imatinib—Dizziness—Epirubicin—liver cancer	3.72e-05	0.000371	CcSEcCtD
Imatinib—Pruritus—Doxorubicin—liver cancer	3.68e-05	0.000368	CcSEcCtD
Imatinib—Vomiting—Epirubicin—liver cancer	3.57e-05	0.000357	CcSEcCtD
Imatinib—Diarrhoea—Doxorubicin—liver cancer	3.56e-05	0.000355	CcSEcCtD
Imatinib—Rash—Epirubicin—liver cancer	3.54e-05	0.000354	CcSEcCtD
Imatinib—Dermatitis—Epirubicin—liver cancer	3.54e-05	0.000354	CcSEcCtD
Imatinib—Headache—Epirubicin—liver cancer	3.52e-05	0.000352	CcSEcCtD
Imatinib—Dizziness—Doxorubicin—liver cancer	3.44e-05	0.000344	CcSEcCtD
Imatinib—Nausea—Epirubicin—liver cancer	3.34e-05	0.000334	CcSEcCtD
Imatinib—Vomiting—Doxorubicin—liver cancer	3.31e-05	0.00033	CcSEcCtD
Imatinib—Rash—Doxorubicin—liver cancer	3.28e-05	0.000328	CcSEcCtD
Imatinib—Dermatitis—Doxorubicin—liver cancer	3.28e-05	0.000327	CcSEcCtD
Imatinib—Headache—Doxorubicin—liver cancer	3.26e-05	0.000325	CcSEcCtD
Imatinib—Nausea—Doxorubicin—liver cancer	3.09e-05	0.000309	CcSEcCtD
Imatinib—LCK—Disease—CDKN1A—liver cancer	2.05e-06	2.17e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—JUN—liver cancer	2.05e-06	2.17e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MAPK8—liver cancer	2.05e-06	2.17e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GOT2—liver cancer	2.05e-06	2.16e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GSTP1—liver cancer	2.04e-06	2.15e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—BRAF—liver cancer	2.03e-06	2.15e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CTNNB1—liver cancer	2.03e-06	2.15e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PIK3CD—liver cancer	2.03e-06	2.15e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—IL6—liver cancer	2.02e-06	2.14e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—PIK3CA—liver cancer	2.02e-06	2.13e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—HMOX1—liver cancer	2.01e-06	2.12e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—ALB—liver cancer	2.01e-06	2.12e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—HRAS—liver cancer	2e-06	2.12e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—PIK3CA—liver cancer	2e-06	2.11e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MMP9—liver cancer	1.99e-06	2.11e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GSTP1—liver cancer	1.99e-06	2.1e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CDKN1A—liver cancer	1.99e-06	2.1e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—STAT3—liver cancer	1.98e-06	2.1e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—CYP1A1—liver cancer	1.98e-06	2.09e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—HMOX1—liver cancer	1.96e-06	2.07e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—KRAS—liver cancer	1.96e-06	2.07e-05	CbGpPWpGaD
Imatinib—KIT—Disease—HRAS—liver cancer	1.95e-06	2.07e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TP53—liver cancer	1.95e-06	2.06e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—PIK3CA—liver cancer	1.95e-06	2.06e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—KRAS—liver cancer	1.94e-06	2.05e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CDKN1B—liver cancer	1.94e-06	2.05e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MAPK8—liver cancer	1.94e-06	2.05e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP2E1—liver cancer	1.92e-06	2.03e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PIK3CB—liver cancer	1.92e-06	2.03e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL6—liver cancer	1.92e-06	2.03e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PIK3CB—liver cancer	1.9e-06	2.02e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3CD—liver cancer	1.9e-06	2.01e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PIK3CB—liver cancer	1.9e-06	2.01e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CASP3—liver cancer	1.9e-06	2.01e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—PIK3CA—liver cancer	1.9e-06	2.01e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL2—liver cancer	1.9e-06	2.01e-05	CbGpPWpGaD
Imatinib—CA9—Metabolism—AKT1—liver cancer	1.89e-06	2e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—VEGFA—liver cancer	1.89e-06	2e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SERPINE1—liver cancer	1.88e-06	1.99e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—STAT3—liver cancer	1.87e-06	1.98e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GSTP1—liver cancer	1.87e-06	1.98e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GSTM1—liver cancer	1.87e-06	1.98e-05	CbGpPWpGaD
Imatinib—KIT—Disease—IL6—liver cancer	1.87e-06	1.98e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—AKT1—liver cancer	1.87e-06	1.97e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—HRAS—liver cancer	1.87e-06	1.97e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.86e-06	1.97e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GSTP1—liver cancer	1.86e-06	1.96e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CCND1—liver cancer	1.85e-06	1.96e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—HRAS—liver cancer	1.85e-06	1.95e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—HMOX1—liver cancer	1.85e-06	1.95e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—JUN—liver cancer	1.85e-06	1.95e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PIK3CB—liver cancer	1.85e-06	1.95e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—MTHFR—liver cancer	1.84e-06	1.95e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CTNNB1—liver cancer	1.83e-06	1.94e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—HMOX1—liver cancer	1.83e-06	1.94e-05	CbGpPWpGaD
Imatinib—LCK—Disease—STAT3—liver cancer	1.83e-06	1.94e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GSTM1—liver cancer	1.83e-06	1.93e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—HPGDS—liver cancer	1.82e-06	1.93e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PPARA—liver cancer	1.81e-06	1.91e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HRAS—liver cancer	1.8e-06	1.91e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYCS—liver cancer	1.8e-06	1.9e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—PIK3CA—liver cancer	1.8e-06	1.9e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CG—liver cancer	1.8e-06	1.9e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MMP9—liver cancer	1.8e-06	1.9e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—VEGFA—liver cancer	1.79e-06	1.89e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CDKN1A—liver cancer	1.79e-06	1.89e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IL6—liver cancer	1.79e-06	1.89e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—PIK3CA—liver cancer	1.78e-06	1.89e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CYP1A1—liver cancer	1.77e-06	1.88e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—STAT3—liver cancer	1.77e-06	1.88e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PIK3CB—liver cancer	1.77e-06	1.88e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—IL6—liver cancer	1.77e-06	1.87e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—AKT1—liver cancer	1.77e-06	1.87e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GOT1—liver cancer	1.77e-06	1.87e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GGT1—liver cancer	1.77e-06	1.87e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—HRAS—liver cancer	1.76e-06	1.86e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MAPK8—liver cancer	1.75e-06	1.85e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MYC—liver cancer	1.74e-06	1.84e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TGFB1—liver cancer	1.74e-06	1.84e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PPARG—liver cancer	1.73e-06	1.83e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CYP1A1—liver cancer	1.73e-06	1.83e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL6—liver cancer	1.73e-06	1.83e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TP53—liver cancer	1.72e-06	1.82e-05	CbGpPWpGaD
Imatinib—KIT—Disease—AKT1—liver cancer	1.72e-06	1.82e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GSTM1—liver cancer	1.72e-06	1.82e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GSTM1—liver cancer	1.71e-06	1.8e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—KRAS—liver cancer	1.7e-06	1.8e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MYC—liver cancer	1.7e-06	1.8e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—RAF1—liver cancer	1.7e-06	1.8e-05	CbGpPWpGaD
Imatinib—LCK—Disease—TGFB1—liver cancer	1.7e-06	1.8e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL6—liver cancer	1.68e-06	1.78e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—HRAS—liver cancer	1.66e-06	1.76e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3CB—liver cancer	1.66e-06	1.75e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MTOR—liver cancer	1.66e-06	1.75e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—MTHFR—liver cancer	1.65e-06	1.75e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—HRAS—liver cancer	1.65e-06	1.74e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MYC—liver cancer	1.65e-06	1.74e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—AKT1—liver cancer	1.65e-06	1.74e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TGFB1—liver cancer	1.64e-06	1.74e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—AKT1—liver cancer	1.63e-06	1.73e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CYP1A1—liver cancer	1.63e-06	1.73e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.62e-06	1.72e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PSMD10—liver cancer	1.62e-06	1.72e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PSMA4—liver cancer	1.62e-06	1.72e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PPARA—liver cancer	1.62e-06	1.72e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CYP1A1—liver cancer	1.62e-06	1.71e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—MTHFR—liver cancer	1.61e-06	1.71e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—VEGFA—liver cancer	1.61e-06	1.71e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—KRAS—liver cancer	1.61e-06	1.7e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—STAT3—liver cancer	1.6e-06	1.69e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—IL6—liver cancer	1.59e-06	1.69e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—AKT1—liver cancer	1.59e-06	1.68e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GSTP1—liver cancer	1.59e-06	1.68e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PPARA—liver cancer	1.58e-06	1.67e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CD—liver cancer	1.58e-06	1.67e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GOT2—liver cancer	1.58e-06	1.67e-05	CbGpPWpGaD
Imatinib—LCK—Disease—KRAS—liver cancer	1.57e-06	1.66e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—HMOX1—liver cancer	1.56e-06	1.66e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—PIK3CA—liver cancer	1.56e-06	1.65e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—ALB—liver cancer	1.56e-06	1.65e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CDKN1B—liver cancer	1.56e-06	1.65e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—AKT1—liver cancer	1.55e-06	1.64e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CG—liver cancer	1.55e-06	1.64e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CASP3—liver cancer	1.53e-06	1.61e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL2—liver cancer	1.52e-06	1.61e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—KRAS—liver cancer	1.52e-06	1.61e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—MTHFR—liver cancer	1.52e-06	1.61e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—MTHFR—liver cancer	1.51e-06	1.59e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PPARG—liver cancer	1.49e-06	1.58e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PPARA—liver cancer	1.49e-06	1.58e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCND1—liver cancer	1.48e-06	1.57e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP2E1—liver cancer	1.48e-06	1.57e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MYC—liver cancer	1.48e-06	1.57e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—JUN—liver cancer	1.48e-06	1.57e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TGFB1—liver cancer	1.48e-06	1.57e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PPARA—liver cancer	1.48e-06	1.56e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—PIK3CA—liver cancer	1.48e-06	1.56e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CTNNB1—liver cancer	1.47e-06	1.56e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—AKT1—liver cancer	1.47e-06	1.55e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GSTM1—liver cancer	1.46e-06	1.54e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.46e-06	1.54e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—AKT1—liver cancer	1.46e-06	1.54e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—HRAS—liver cancer	1.45e-06	1.53e-05	CbGpPWpGaD
Imatinib—LCK—Disease—PIK3CA—liver cancer	1.44e-06	1.53e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MMP9—liver cancer	1.44e-06	1.53e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CDKN1A—liver cancer	1.44e-06	1.52e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TP53—liver cancer	1.43e-06	1.51e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MAPK8—liver cancer	1.4e-06	1.48e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PIK3CA—liver cancer	1.4e-06	1.48e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CG—liver cancer	1.39e-06	1.47e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYCS—liver cancer	1.39e-06	1.47e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IL6—liver cancer	1.38e-06	1.47e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP1A1—liver cancer	1.38e-06	1.46e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CB—liver cancer	1.38e-06	1.46e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—KRAS—liver cancer	1.37e-06	1.45e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—HRAS—liver cancer	1.37e-06	1.45e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GGT1—liver cancer	1.36e-06	1.44e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GOT1—liver cancer	1.36e-06	1.44e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CD—liver cancer	1.36e-06	1.44e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CG—liver cancer	1.36e-06	1.43e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TP53—liver cancer	1.35e-06	1.43e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PPARG—liver cancer	1.34e-06	1.42e-05	CbGpPWpGaD
Imatinib—LCK—Disease—HRAS—liver cancer	1.34e-06	1.41e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.33e-06	1.41e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PPARG—liver cancer	1.31e-06	1.38e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL6—liver cancer	1.31e-06	1.38e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—VEGFA—liver cancer	1.29e-06	1.37e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—HRAS—liver cancer	1.29e-06	1.37e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—MTHFR—liver cancer	1.29e-06	1.36e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—STAT3—liver cancer	1.28e-06	1.36e-05	CbGpPWpGaD
Imatinib—LCK—Disease—IL6—liver cancer	1.28e-06	1.35e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CG—liver cancer	1.28e-06	1.35e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—AKT1—liver cancer	1.28e-06	1.35e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CG—liver cancer	1.27e-06	1.34e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PPARA—liver cancer	1.26e-06	1.34e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PIK3CA—liver cancer	1.26e-06	1.33e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL6—liver cancer	1.24e-06	1.31e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PPARG—liver cancer	1.23e-06	1.3e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTP1—liver cancer	1.22e-06	1.3e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PPARG—liver cancer	1.22e-06	1.29e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CD—liver cancer	1.22e-06	1.29e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TP53—liver cancer	1.22e-06	1.29e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—HMOX1—liver cancer	1.21e-06	1.28e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—AKT1—liver cancer	1.21e-06	1.28e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ALB—liver cancer	1.21e-06	1.28e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CD—liver cancer	1.19e-06	1.26e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MYC—liver cancer	1.19e-06	1.26e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TGFB1—liver cancer	1.19e-06	1.26e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CB—liver cancer	1.19e-06	1.25e-05	CbGpPWpGaD
Imatinib—LCK—Disease—AKT1—liver cancer	1.18e-06	1.25e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ALB—liver cancer	1.18e-06	1.24e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PIK3CA—liver cancer	1.17e-06	1.24e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—HRAS—liver cancer	1.17e-06	1.23e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PIK3CA—liver cancer	1.16e-06	1.23e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PIK3CA—liver cancer	1.16e-06	1.23e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—AKT1—liver cancer	1.14e-06	1.21e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.14e-06	1.2e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PIK3CA—liver cancer	1.13e-06	1.19e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTM1—liver cancer	1.12e-06	1.19e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CD—liver cancer	1.12e-06	1.19e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL6—liver cancer	1.12e-06	1.18e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CD—liver cancer	1.11e-06	1.18e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ALB—liver cancer	1.11e-06	1.17e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KRAS—liver cancer	1.1e-06	1.16e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ALB—liver cancer	1.1e-06	1.16e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CG—liver cancer	1.08e-06	1.15e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PIK3CA—liver cancer	1.08e-06	1.14e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP1A1—liver cancer	1.07e-06	1.13e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CB—liver cancer	1.06e-06	1.13e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PPARG—liver cancer	1.04e-06	1.11e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CB—liver cancer	1.04e-06	1.1e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—AKT1—liver cancer	1.03e-06	1.09e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3CA—liver cancer	1.01e-06	1.07e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—MTHFR—liver cancer	9.94e-07	1.05e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CB—liver cancer	9.79e-07	1.04e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TP53—liver cancer	9.78e-07	1.03e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PPARA—liver cancer	9.75e-07	1.03e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CB—liver cancer	9.7e-07	1.03e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—AKT1—liver cancer	9.57e-07	1.01e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CD—liver cancer	9.51e-07	1.01e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—AKT1—liver cancer	9.48e-07	1e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—AKT1—liver cancer	9.47e-07	1e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ALB—liver cancer	9.39e-07	9.94e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—HRAS—liver cancer	9.35e-07	9.9e-06	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—AKT1—liver cancer	9.19e-07	9.73e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL6—liver cancer	8.95e-07	9.47e-06	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—AKT1—liver cancer	8.83e-07	9.34e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CA—liver cancer	8.39e-07	8.88e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CG—liver cancer	8.35e-07	8.84e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CB—liver cancer	8.29e-07	8.77e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—AKT1—liver cancer	8.26e-07	8.74e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PPARG—liver cancer	8.06e-07	8.53e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CD—liver cancer	7.34e-07	7.77e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ALB—liver cancer	7.25e-07	7.67e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CA—liver cancer	7.23e-07	7.65e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—AKT1—liver cancer	6.86e-07	7.25e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CA—liver cancer	6.49e-07	6.86e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CB—liver cancer	6.4e-07	6.77e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CA—liver cancer	6.33e-07	6.7e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CA—liver cancer	5.97e-07	6.31e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CA—liver cancer	5.92e-07	6.26e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—AKT1—liver cancer	5.9e-07	6.25e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—AKT1—liver cancer	5.3e-07	5.61e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—AKT1—liver cancer	5.17e-07	5.47e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CA—liver cancer	5.06e-07	5.35e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—AKT1—liver cancer	4.87e-07	5.16e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—AKT1—liver cancer	4.83e-07	5.11e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—AKT1—liver cancer	4.13e-07	4.37e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CA—liver cancer	3.9e-07	4.13e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AKT1—liver cancer	3.19e-07	3.37e-06	CbGpPWpGaD
